TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28936626
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not receiving specific ICU procedures (ventilation, vasoactive drugs, renal replacement therapy)
Study: 28936952
Drug: Injection test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection test with esophageal balloon catheter
Study: 28938419
Drug: Urinary concentrations
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary concentrations of LH after 3 months of GnRH treatment
Study: 28938918
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) at dose level 3 (36 Gy/3)
Study: 28938918
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) in combination with pazopanib
Study: 28939546
Drug: Smart technology
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smart technology intervention (daily measurements with smartphone-compatible ECG device, BP monitor, weight scale, activity tracker; two electronic visits)
Study: 28941036
Drug: SUMO4 rs237025
Normalized name: Sumox
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUMO4 rs237025 G allele
Study: 28941623
Drug: MenACWY-D vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-D vaccine
Study: 28944067
Drug: Probiotic intervention
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic intervention (two daily tablets totalling 1.4×10)
Study: 28944714
Drug: Gymnemic acids
Normalized name: GYMNEMA SYLVESTRIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gymnemic acids (GA) lozenge
Study: 28945848
Drug: Panitumumab in
Normalized name: panitumumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab in combination with irinotecan
Study: 28945911
Drug: E/C/F/TDF therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/C/F/TDF therapy, no LXR agonist
Study: 28945911
Drug: E/C/F/TDF therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/C/F/TDF therapy, LXR agonist
Study: 28945911
Drug: Non-HIV-infected subjects,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HIV-infected subjects, no LXR agonist
Study: 28945911
Drug: Non-HIV-infected subjects,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HIV-infected subjects, LXR agonist
Study: 28946874
Drug: Periurethral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periurethral injection of autologous regenerative cells from adipose tissue using the Celution® system
Study: 28948137
Drug: Evidence-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based intervention to promote colorectal cancer (CRC) screening; specific details on dosage and duration not available.
Study: 28948137
Drug: Implementation strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation strategies for the evidence-based intervention; specific details on dosage and duration not available.
Study: 28948656
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Aliskiren and Enalapril
Study: 28950146
Drug: Buparlisib 80
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib 80 mg/d + Lapatinib 1000 mg/d
Study: 28950146
Drug: Buparlisib 40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib 40, 60, or 80 mg + Lapatinib 750, 1000, or 1250 mg
Study: 28950288
Drug: selumetinib 50
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selumetinib 50 or 75 mg plus gemcitabine/cisplatin (n=10)
Study: 28950288
Drug: selumetinib 50
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selumetinib 50 mg plus gemcitabine/carboplatin (n=9)
Study: 28950288
Drug: selumetinib 100
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selumetinib 100 mg plus pemetrexed/carboplatin (n=21)
Study: 28950288
Drug: selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selumetinib 75 mg plus pemetrexed/cisplatin (n=15)
Study: 28950288
Drug: selumetinib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: selumetinib (various doses) plus chemotherapy
Study: 28950288
Drug: selumetinib plus
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selumetinib plus chemotherapy
Study: 28950288
Drug: selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selumetinib 75 mg BID with standard doses of pemetrexed/carboplatin or pemetrexed/cisplatin
Study: 28950298
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg i.v. every 3 weeks until loss of clinical benefit
Study: 28950298
Drug: Other systemic
Normalized name: Other systemic hemostatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other systemic therapy
Study: 28950298
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further systemic therapy
Study: 28950338
Drug: Afatinib (pan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (pan HER-family kinase inhibitor)
Study: 28951336
Drug: Insulin-treated patients
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-treated patients with type 1 diabetes
Study: 28951336
Drug: Insulin-treated patients
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-treated patients with type 2 diabetes
Study: 28952191
Drug: STARD3 (hub
Approvals — FDA: no, EMA: no, PMDA: no
Description: STARD3 (hub gene for energy metabolism module)
Study: 28952191
Drug: G-protein coupled
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-protein coupled receptor protein signaling pathway
Study: 28954285
Drug: Proton-based stereotactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-based stereotactic body radiation therapy (SBRT) with a median dose of 40 GyE (range = 30-50 GyE) in five fractions.
Study: 28956281
Drug: Autoinjector for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autoinjector for self-administration of subcutaneous belimumab
Study: 28956335
Drug: PDE inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDE inhibitors
Study: 28956335
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide (NO)/cGMP pathway and NMDA receptor signaling
Study: 28958347
Drug: GDF-15 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDF-15 therapy
Study: 28960029
Drug: Submillisievert chest
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Submillisievert chest computed tomography (CT) scan (effective dose, 0.19-0.25 millisievert)
Study: 28960096
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cells (MSCs) at doses of 0.3, 1.0, and 3.0 million cells/kg (up to 250 million cells)
Study: 28961812
Drug: Meropenem 2000
Normalized name: meropenem 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 2000 mg/6 h by intermittent (30 min) or prolonged (3 h) infusion for A. baumannii
Study: 28961812
Drug: Meropenem 6000
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem 6000 mg/day by continuous infusion for A. baumannii
Study: 28961812
Drug: Meropenem 2000
Normalized name: meropenem 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 2000 mg/8 h or 1000 mg/6 h for P. aeruginosa
Study: 28961812
Drug: Meropenem 1000
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1000 mg/8 h for patients with CLCR ≤ 100 mL/min
Study: 28962047
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg Dexamethasone Suppression Test (DST)
Study: 28962047
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg Dexamethasone Suppression Test (DST)
Study: 28963781
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy (356 patients total)
Study: 28964314
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg rocuronium
Study: 28964826
Drug: Mixed model
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed model (HL) 2d/week consisting of H training 1d/week and L training 1d/week
Study: 28965093
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment for hypertension (antihypertensive medication)
Study: 28965093
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment for dyslipidaemia (statin)
Study: 28965093
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment for diabetes (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker)
Study: 28965093
Drug: Treatment gap
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment gap in dyslipidaemia
Study: 28965185
Drug: Erdafitinib 2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdafitinib 2, 4, or 6 mg daily dosing schedule
Study: 28965185
Drug: Erdafitinib 10
Normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erdafitinib 10 mg or 12 mg intermittent dosing schedule
Study: 28965185
Drug: Erdafitinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdafitinib (all doses)
Study: 28967387
Drug: Bacteriologic criterion
Normalized name: Bacteriolysin sal-1 (staphylococcus phage sap-1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteriologic criterion of ≥10,000 colony forming units/mL of a single organism
Study: 28968874
Drug: Non-adjuvanted influenza
Normalized name: Influenza, adjuvanted, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted influenza A/California/7/2009 (pH1N1) vaccine
Study: 28970161
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with colistin (9 million UI/day) and tigecycline (100 mg/day)
Study: 28970161
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with colistin (9 million UI/day)
Study: 28970161
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with colistin and tigecycline
Study: 28970161
Drug: Empirical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical therapy with colistin
Study: 28970161
Drug: Renal dysfunction
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal dysfunction before treatment
Study: 28970332
Drug: Visual assessments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual assessments of fundic accommodation by trained readers (nuclear medicine and radiology physicians) during solid-meal gastric emptying scintigraphy (GES)
Study: 28971861
Drug: Micafungin; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin; specific dosage and duration not mentioned.
Study: 28971900
Drug: Buparlisib 100
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib 100 mg once daily until progression, intolerance, or withdrawal of consent
Study: 28971900
Drug: Buparlisib 100
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib 100 mg once daily
Study: 28972011
Drug: Oral leniolisib
Normalized name: Leniolisib
DrugBank: Leniolisib (DB16217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral leniolisib (CDZ173)
Study: 28973026
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum phosphate in patients with serum albumin lower than 3.9 g/dL
Study: 28973164
Drug: Isoglycemic Intravenous
Normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoglycemic Intravenous Glucose Infusion (IIGI)
Study: 28973403
Drug: Rilotumumab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab monotherapy (10 or 20 mg/kg IV every 2 weeks)
Study: 28973403
Drug: Rilotumumab in
Normalized name: Rilotumumab
DrugBank: Rilotumumab (DB11972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab in combination with cisplatin (80 mg/m2 on Day 1) and capecitabine (1000 mg/m2 twice daily on Days 1-14 of every 21-day cycle)
Study: 28973403
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events related to any treatment
Study: 28973403
Drug: Dose-limiting toxicities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-limiting toxicities (DLTs)
Study: 28973520
Drug: TAVR vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAVR vs medical treatment, n=165
Study: 28973622
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d of biotin supplementation for 7 days
Study: 28974059
Drug: Augmented pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented pulse pressure variation (PPV12) induced by 2-min ventilation with a tidal volume (V T ) of 12 ml kg -1
Study: 28974059
Drug: Standard pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pulse pressure variation (PPV8) with a tidal volume of 8 ml kg -1
Study: 28975039
Drug: Creative music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creative music therapy (CMT), approximately 20 minutes duration, three times per week, delivered by a trained music therapist singing in lullaby style, adjusted to the infant's rhythm and affect.
Study: 28976556
Drug: SAR260301 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR260301 (100 mg to 440 mg once daily)
Study: 28976817
Drug: Lenti-D gene
Normalized name: Lenti-d
DrugBank: Elivaldogene tavalentivec (DB19095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenti-D gene therapy (autologous CD34+ cells transduced with elivaldogene tavalentivec)
Study: 28976817
Drug: Lenti-D gene
Normalized name: Lenti-d
DrugBank: Elivaldogene tavalentivec (DB19095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenti-D gene therapy
Study: 28977361
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (unoperated)
Study: 28977630
Drug: Antinuclear antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antinuclear antibodies (ACA)
Study: 28978797
Drug: Aprepitant 375
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 375 mg per day for 28 days
Study: 28978801
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (5,000 IU cholecalciferol daily for 90 days)
Study: 28979661
Drug: Ingenol Mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol Mebutate Gel 0.015%
Study: 28980004
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin 1.8 mg/kg infused over 30 minutes every 21 days
Study: 28980446
Drug: BIVV009 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIVV009 (60 mg/kg, 4 weekly doses)
Study: 28982495
Drug: High-energy breakfast
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy breakfast (contributing to >20% of total daily energy intake)
Study: 28982495
Drug: Skipping breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skipping breakfast (consuming <5% of total daily energy)
Study: 28982495
Drug: Low-energy breakfast
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy breakfast (contributing between 5% and 20% of total daily energy intake)
Study: 28982667
Drug: Excretion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excretion of endogenous cholesterol
Study: 28982814
Drug: Emotion regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion regulation group therapy (ERGT)
Study: 28983018
Drug: Moxetumomab pasudotox
Normalized name: Moxetumomab Pasudotox
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Moxetumomab pasudotox (30 µg/kg every other day for 6 doses)
Study: 28983018
Drug: Moxetumomab pasudotox
Normalized name: Moxetumomab Pasudotox
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Moxetumomab pasudotox (50 µg/kg for 10 doses)
Study: 28983018
Drug: Moxetumomab pasudotox
Normalized name: Moxetumomab Pasudotox
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Moxetumomab pasudotox (40 µg/kg for 10 doses)
Study: 28983018
Drug: Moxetumomab pasudotox
Normalized name: Moxetumomab Pasudotox
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Moxetumomab pasudotox (50 µg/kg × 6 doses)
Study: 28984517
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) - either intensity modulated (IMRT) or 3D conformal (3DCRT), 54 Gy in 30 fractions
Study: 28985241
Drug: High-Salt (HS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Salt (HS) diet (18.0 g/day NaCl)
Study: 28985241
Drug: Low-Salt (LS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Salt (LS) diet (3.0 g/day NaCl)
Study: 28985241
Drug: High-Salt +
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Salt + K+ (HS + K+) diet (18.0 g/day NaCl and 4.5 g/day KCl)
Study: 28986407
Drug: USPIO-enhanced MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: USPIO-enhanced MRI (ferumoxytol, 4 mg/kg)
Study: 28986931
Drug: Standardised anaesthesia,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised anaesthesia, intravenous coloading, and prophylactic vasopressor treatment
Study: 28988934
Drug: WTX101 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WTX101 monotherapy at a starting dose of 15-60 mg/day for the first 4-8 weeks, with response-guided individualised dosing for the remaining weeks up to week 24.
Study: 28988934
Drug: WTX101 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WTX101 monotherapy
Study: 28989706
Drug: Standard Dialectical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Dialectical Behaviour Therapy (DBT) for 12 months
Study: 28991061
Drug: 0.5% Ropivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Ropivacaine, initial volume 30 mL, adjusted by 2 mL based on previous subject's response
Study: 28991112
Drug: Dexmedetomidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine administered over 15 minutes, dosage determined by the Dixon up-and-down method.
Study: 28994660
Drug: Rilpivirine (RPV)
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine (RPV) 25 mg, once daily
Study: 29016235
Drug: Telemedicine support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine support group intervention using encrypted tablet-based videoconferencing.
Study: 29660005
Drug: Cabozantinib 140
Normalized name: cabozantinib 140 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 140 mg/day
Study: 29017455
Drug: Remifentanil adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil adjusted to approximately 6.5 ng/mL before head fixation
Study: 29017845
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of daily toothbrushing
Study: 29017994
Drug: BPTrack, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPTrack, a clinical pharmacist-led mHealth intervention for hypertension management, involving home blood pressure monitoring and medication adherence over a 12-week period.
Study: 29018537
Drug: AMG 811
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 811 (6, 20 or 60 mg)
Study: 29018537
Drug: AMG 811
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 811 (20, 60 or 120 mg)
Study: 29021813
Drug: Phytosterols 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterols 800 mg
Study: 29021813
Drug: Red yeast
Normalized name: red yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red yeast rice standardized to contain 5 mg monacolins
Study: 29021813
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of phytosterols and red yeast rice
Study: 29025008
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg qd
Study: 29025008
Drug: Carvedilol 12.5
Normalized name: carvedilol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5 mg bid
Study: 29025008
Drug: Carvedilol with
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol with inhaled LAMA (tiotropium) and LABA (formoterol)
Study: 29026685
Drug: Carfilzomib infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib infusion (27 and 56 mg/m2)
Study: 29027607
Drug: Patient-reported outcome
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-reported outcome measure (PRO) for barriers to antiretroviral therapy (ART) adherence